Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
Why Is Pulmonx Corporation (LUNG) Stock Up +20.24% Today?

Why Is Pulmonx Corporation (LUNG) Stock Up +20.24% Today?

Key Takeaways

  • Pulmonx Corporation (LUNG) shares climbed about 20% on Thursday, extending a sharp two-session rally to roughly $3.03 from a prior close of $2.52.
  • Primary catalyst: A post-earnings momentum run following better-than-expected third-quarter 2026 results released after Tuesday's close, headlined by a return to year-over-year revenue growth.
  • Secondary driver: Wall Street analysts responded favorably, with Stifel raising its price target to $4 from $2.50 and Canaccord setting a $5 target.
  • Broader context: The move reflects continued follow-through buying in a thinly traded small-cap medical-device name after the prior session's roughly 27% surge.
  • What traders are watching next: Fourth-quarter execution, the resumption of China shipments, and upcoming investor conference appearances in November.
  • For additional detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated pages for deeper analysis.
  • Interested in automated trading signals? Review the latest Trending AI Robots to see which strategies are performing best in current conditions.

Opening Summary

Pulmonx Corporation (LUNG), a Redwood City, California-based medical-technology company specializing in minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease (COPD), extended its rally on Thursday. The company's flagship Zephyr Endobronchial Valve is used to treat patients with severe lung disease who remain symptomatic despite medical management. Shares advanced roughly 20.24%, or about $0.51, to trade near $3.03, up from the prior session's close of $2.52, as investors continued to digest a stronger-than-expected quarterly report and a wave of supportive analyst commentary.

Earnings Beat and Return to Growth

The dominant catalyst behind the two-day move was Pulmonx's third-quarter 2026 financial results, reported after the market closed on Tuesday. The company posted revenue of $22.8 million, a 6% increase from $21.5 million a year earlier and ahead of analyst expectations of roughly $21.9 million. Notably, the quarter marked Pulmonx's first return to year-over-year revenue growth in both its U.S. and international businesses since the current management team rejoined the company.

The bottom line also improved markedly. Pulmonx reported a GAAP net loss of $8.4 million, or $0.19 per share, narrowing from a loss of $0.34 per share in the prior-year period and beating the consensus estimate of a $0.26 loss. Adjusted EBITDA loss narrowed by nearly 60% to $3.5 million, while gross margin improved to 76% from 75%. Management also reiterated its full-year 2026 revenue guidance of $90 million to $92 million, reinforcing confidence in the commercial turnaround.

Analyst Support and Price-Target Increases

The fundamental beat was amplified by fresh analyst endorsements. Stifel raised its price target on LUNG to $4.00 from $2.50 while maintaining a Buy rating, and Canaccord Genuity reiterated its Buy rating with a $5.00 target. The upgrades underscored the view that Pulmonx's rebuilt U.S. sales force and disciplined expense management are translating into accelerating commercial traction. Management noted it added eight new U.S. treating centers during the quarter and has substantially filled its open sales territories.

Market Context and Trading Activity

Trading in LUNG has been exceptionally heavy during the rally, with the prior session's volume running well into the millions of shares versus a far lower typical daily average — a clear sign of elevated conviction among buyers reacting to the earnings surprise. The stock has now broken decisively above its 50-day moving average near $2.02 and its 200-day moving average near $1.65, marking a meaningful technical breakout for a small-cap name with a market capitalization measured in the low hundreds of millions of dollars.

The move is largely company-specific rather than a broad sector rotation, though it aligns with a generally favorable backdrop for medical-device equities. The two-day surge also reflects the outsized percentage moves typical of low-priced, thinly traded stocks, where even moderate buying pressure can produce pronounced price swings.

What Comes Next for LUNG

Looking ahead, investors will monitor whether Pulmonx can sustain its return to growth through the fourth quarter, which is expected to carry the company's full-year revenue toward the low $90 million range. The resumption of shipments to its Chinese distributor, anticipated by early next year, represents a potential incremental tailwind, though management has characterized China as a relatively small and lumpy contributor to overall revenue. Upcoming appearances at the Canaccord Genuity MedTech Forum and the Stifel Healthcare Conference in November could provide additional visibility into commercial execution and the company's 2027 outlook.

Risks remain. The company is still unprofitable, continues to burn cash, and relies heavily on a single flagship product family. Insider selling has also been a recurring theme in recent quarters. As such, the sustainability of the current rally will likely hinge on evidence that revenue growth and margin improvement persist into 2027.

Trending AI Robots

Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to evaluate. Explore the page to see which automated strategies are leading the market right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LUNG

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


LUNG's Indicator enters downward trend

The Aroon Indicator for LUNG entered a downward trend on October 23, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 202 similar instances where the Aroon Indicator formed such a pattern. In 185 of the 202 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for LUNG moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 27 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.

The Moving Average Convergence Divergence Histogram (MACD) for LUNG turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 44 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

LUNG broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on LUNG as a result. In 70 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

LUNG moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for LUNG crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.

Following a +7.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in 214 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.805) is normal, around the industry mean (4.142). P/E Ratio (-2.226) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.932) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
700 Chesapeake Drive
Phone
+1 650 364-0400
Employees
296
Web
https://www.pulmonx.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.